A national vaccine perception survey has revealed that some of Ghana’s most urbanised regions, including the Central and Ashanti Regions, are recording lower levels of vaccine acceptance even though residents have greater access to health information.
The findings, released by the National Vaccine Institute (National Vaccine Institute), show that rural areas—particularly in northern Ghana and the Oti Region—demonstrate comparatively higher trust in vaccines.
The study, which sampled 13,905 respondents across all 16 regions and 55 districts, is described as one of the most comprehensive assessments of vaccine attitudes and perceptions of locally produced health products in Ghana.
Overall, the survey paints a largely positive national picture, with 89.7% of respondents expressing confidence in vaccines and 94.2% supporting collective responsibility for ensuring vaccine availability.
It also found strong willingness toward locally manufactured vaccines, with 71.3% of respondents indicating readiness to accept Ghana-made vaccines once production begins in 2027.
Despite this optimism, the report highlights significant awareness gaps, noting that only 14.3% of respondents are aware of Ghana’s plans to produce vaccines locally.
Trust in health professionals remains high, with 87.8% of respondents expressing confidence in doctors and nurses, alongside strong trust in institutions such as the Ghana Health Service and the Food and Drugs Authority.
However, the survey identified barriers that could affect uptake, including cost concerns, distance to health facilities, and weaknesses in cold chain and vaccine storage systems, particularly in rural areas.
Chief Executive Officer of the National Vaccine Institute, Dr Sodzi Sodzi-Tettey, said Ghana has a strong foundation of vaccine confidence but must address misinformation, regional disparities, and awareness gaps around local vaccine production.
He noted that targeted communication strategies and public education campaigns will be critical as Ghana prepares for local vaccine manufacturing, expected to begin in 2027 as part of efforts to strengthen health security and pharmaceutical independence.
